Global Neurodegenerative Diseases Therapeutics Market Size Study, by Indication (Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Others) and Type (Mammography, Breast Ultrasound, Breast MRI, Image-guided Breast Biopsy, Other Imaging Techniques) and Regional Forecasts 2022-2032
Global Neurodegenerative Diseases Therapeutics Market is valued approximately at USD 52.05 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.51% over the forecast period 2024-2032. Neurodegenerative diseases therapeutics encompasses a broad spectrum of treatments aimed at managing and potentially curing diseases that progressively destroy brain cells, such as Alzheimer's, Parkinson's, and Huntington's diseases. These debilitating conditions result in a decline in cognitive, motor, and emotional functions, making the development of effective therapeutics critically important. The market's growth is driven by several factors, including a robust drug development pipeline bringing innovative treatments to various health conditions, particularly neurodegenerative diseases, and significant research funding dedicated to these conditions. Additionally, the availability of highly sensitive diagnostic modalities enhances early detection and diagnosis, improving patient outcomes and contributing to the market's expansion.
The market dynamics and customer landscape reveal that the residential sector is witnessing significant growth due to advancements in automatic cleaning technologies, particularly in the healthcare setting. Innovations in suction mechanisms, battery-powered and electric cleaning robots, and enhanced compatibility with Wi-Fi and app connectivity are transforming cleaning and maintenance in healthcare facilities. These innovations ensure thorough cleaning and sanitization, critical for environments dealing with neurodegenerative diseases. The increasing incidence of neurodegenerative diseases is a key driver of market growth. For instance, as per the Centers for Disease Control and Prevention (CDC), Alzheimer's disease affected around 6.2 million people in the US in 2021 and is expected to nearly triple to 14 million by 2060. The strong pipeline of drugs under development, such as ABT-SLV187 by AbbVie and APL-130277 by Sunovion, highlights the ongoing research and development efforts aimed at addressing these diseases. The introduction of new drugs and therapies is expected to drive market growth during the forecast period.
A significant market trend is the aging population, which is expected to nearly double from 12% to 22% between 2015 and 2050, according to the World Health Organization (WHO). This demographic shift increases the prevalence of neurodegenerative diseases, thereby driving demand for therapeutic interventions. In regions such as Sub-Saharan Africa, neurological disorders are commonly found in the elderly, further supporting market growth. One of the major challenges to market growth is the lack of disease-modifying therapies. While some neurodegenerative diseases, such as Alzheimer's and Parkinson's, have drugs that provide symptomatic relief, there are no approved therapies that impact the underlying disease processes for conditions like Huntington's disease. This gap in treatment options presents a significant challenge to market growth.
The key regions considered for the global Neurodegenerative Diseases Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Neurodegenerative Diseases Therapeutics Market in terms of revenue. The market growth in the region is being attributed to factors including rapidly aging population, increasing prevalence of neurological disorders like Alzheimer's and Parkinson's, substantial investments in research and development, and robust healthcare infrastructure. These factors contribute to a high demand for effective treatments and drive market growth. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rapidly aging population, increasing prevalence of neurological disorders, rising healthcare expenditure, and growing awareness about available treatments. These factors, coupled with the increasing penetration of western lifestyles and dietary habits, are contributing to the market's growth.
Major market players included in this report are:
AB Science SA
Acadia Pharmaceuticals Inc.
H Lundbeck AS
Mitsubishi Chemical Corp.
Novartis AG
Sanofi SA
Teva Pharmaceutical Industries Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co., Inc.
AbbVie Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd
The detailed segments and sub-segment of the market are explained below:
By Indication:
North America
The market dynamics and customer landscape reveal that the residential sector is witnessing significant growth due to advancements in automatic cleaning technologies, particularly in the healthcare setting. Innovations in suction mechanisms, battery-powered and electric cleaning robots, and enhanced compatibility with Wi-Fi and app connectivity are transforming cleaning and maintenance in healthcare facilities. These innovations ensure thorough cleaning and sanitization, critical for environments dealing with neurodegenerative diseases. The increasing incidence of neurodegenerative diseases is a key driver of market growth. For instance, as per the Centers for Disease Control and Prevention (CDC), Alzheimer's disease affected around 6.2 million people in the US in 2021 and is expected to nearly triple to 14 million by 2060. The strong pipeline of drugs under development, such as ABT-SLV187 by AbbVie and APL-130277 by Sunovion, highlights the ongoing research and development efforts aimed at addressing these diseases. The introduction of new drugs and therapies is expected to drive market growth during the forecast period.
A significant market trend is the aging population, which is expected to nearly double from 12% to 22% between 2015 and 2050, according to the World Health Organization (WHO). This demographic shift increases the prevalence of neurodegenerative diseases, thereby driving demand for therapeutic interventions. In regions such as Sub-Saharan Africa, neurological disorders are commonly found in the elderly, further supporting market growth. One of the major challenges to market growth is the lack of disease-modifying therapies. While some neurodegenerative diseases, such as Alzheimer's and Parkinson's, have drugs that provide symptomatic relief, there are no approved therapies that impact the underlying disease processes for conditions like Huntington's disease. This gap in treatment options presents a significant challenge to market growth.
The key regions considered for the global Neurodegenerative Diseases Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Neurodegenerative Diseases Therapeutics Market in terms of revenue. The market growth in the region is being attributed to factors including rapidly aging population, increasing prevalence of neurological disorders like Alzheimer's and Parkinson's, substantial investments in research and development, and robust healthcare infrastructure. These factors contribute to a high demand for effective treatments and drive market growth. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rapidly aging population, increasing prevalence of neurological disorders, rising healthcare expenditure, and growing awareness about available treatments. These factors, coupled with the increasing penetration of western lifestyles and dietary habits, are contributing to the market's growth.
Major market players included in this report are:
AB Science SA
Acadia Pharmaceuticals Inc.
H Lundbeck AS
Mitsubishi Chemical Corp.
Novartis AG
Sanofi SA
Teva Pharmaceutical Industries Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co., Inc.
AbbVie Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd
The detailed segments and sub-segment of the market are explained below:
By Indication:
- Multiple sclerosis
- Alzheimer’s disease
- Parkinson’s disease
- Huntington’s disease
- Others
- Mammography
- Breast ultrasound
- Breast MRI
- Image-guided breast biopsy
- Other imaging techniques
North America
- U.S.
- Canada
- UK
- Germany
- France
- Spain
- Italy
- ROE
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Brazil
- Mexico
- RoLA
- Saudi Arabia
- South Africa
- RoMEA
- Historical year – 2022
- Base year – 2023
- Forecast period – 2024 to 2032
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with country-level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
CHAPTER 1. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET EXECUTIVE SUMMARY
1.1. Global Neurodegenerative Diseases Therapeutics Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Indication
1.3.2. By Type
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing Incidence of Neurodegenerative Diseases
3.1.2. Robust Drug Development Pipeline
3.1.3. High Research Funding
3.2. Market Challenges
3.2.1. Lack of Disease-Modifying Therapies
3.2.2. High Cost of Development
3.3. Market Opportunities
3.3.1. Aging Population
3.3.2. Advancements in Diagnostic Modalities
3.3.3. Emerging Markets
CHAPTER 4. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET SIZE & FORECASTS BY INDICATION 2022-2032
5.1. Segment Dashboard
5.2. Global Neurodegenerative Diseases Therapeutics Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Multiple sclerosis
5.2.2. Alzheimer’s disease
5.2.3. Parkinson’s disease
5.2.4. Huntington’s disease
5.2.5. Others
CHAPTER 6. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET SIZE & FORECASTS BY TYPE 2022-2032
6.1. Segment Dashboard
6.2. Global Neurodegenerative Diseases Therapeutics Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Mammography
6.2.2. Breast ultrasound
6.2.3. Breast MRI
6.2.4. Image-guided breast biopsy
6.2.5. Other imaging techniques
CHAPTER 7. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022-2032
7.1. North America Neurodegenerative Diseases Therapeutics Market
7.1.1. U.S. Neurodegenerative Diseases Therapeutics Market
7.1.1.1. Indication breakdown size & forecasts, 2022-2032
7.1.1.2. Type breakdown size & forecasts, 2022-2032
7.1.2. Canada Neurodegenerative Diseases Therapeutics Market
7.2. Europe Neurodegenerative Diseases Therapeutics Market
7.2.1. U.K. Neurodegenerative Diseases Therapeutics Market
7.2.2. Germany Neurodegenerative Diseases Therapeutics Market
7.2.3. France Neurodegenerative Diseases Therapeutics Market
7.2.4. Spain Neurodegenerative Diseases Therapeutics Market
7.2.5. Italy Neurodegenerative Diseases Therapeutics Market
7.2.6. Rest of Europe Neurodegenerative Diseases Therapeutics Market
7.3. Asia-Pacific Neurodegenerative Diseases Therapeutics Market
7.3.1. China Neurodegenerative Diseases Therapeutics Market
7.3.2. India Neurodegenerative Diseases Therapeutics Market
7.3.3. Japan Neurodegenerative Diseases Therapeutics Market
7.3.4. Australia Neurodegenerative Diseases Therapeutics Market
7.3.5. South Korea Neurodegenerative Diseases Therapeutics Market
7.3.6. Rest of Asia Pacific Neurodegenerative Diseases Therapeutics Market
7.4. Latin America Neurodegenerative Diseases Therapeutics Market
7.4.1. Brazil Neurodegenerative Diseases Therapeutics Market
7.4.2. Mexico Neurodegenerative Diseases Therapeutics Market
7.4.3. Rest of Latin America Neurodegenerative Diseases Therapeutics Market
7.5. Middle East & Africa Neurodegenerative Diseases Therapeutics Market
7.5.1. Saudi Arabia Neurodegenerative Diseases Therapeutics Market
7.5.2. South Africa Neurodegenerative Diseases Therapeutics Market
7.5.3. Rest of Middle East & Africa Neurodegenerative Diseases Therapeutics Market
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. Company
8.1.2. Company
8.1.3. Company
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. AB Science SA
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Acadia Pharmaceuticals Inc.
8.3.3. H Lundbeck AS
8.3.4. Mitsubishi Chemical Corp.
8.3.5. Novartis AG
8.3.6. Sanofi SA
8.3.7. Teva Pharmaceutical Industries Ltd.
8.3.8. Amgen Inc.
8.3.9. AstraZeneca PLC
8.3.10. Eli Lilly and Company
8.3.11. GlaxoSmithKline plc
8.3.12. Merck & Co., Inc.
8.3.13. AbbVie Inc.
8.3.14. Biogen Inc.
8.3.15. F. Hoffmann La Roche Ltd
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
1.1. Global Neurodegenerative Diseases Therapeutics Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Indication
1.3.2. By Type
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing Incidence of Neurodegenerative Diseases
3.1.2. Robust Drug Development Pipeline
3.1.3. High Research Funding
3.2. Market Challenges
3.2.1. Lack of Disease-Modifying Therapies
3.2.2. High Cost of Development
3.3. Market Opportunities
3.3.1. Aging Population
3.3.2. Advancements in Diagnostic Modalities
3.3.3. Emerging Markets
CHAPTER 4. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET SIZE & FORECASTS BY INDICATION 2022-2032
5.1. Segment Dashboard
5.2. Global Neurodegenerative Diseases Therapeutics Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Multiple sclerosis
5.2.2. Alzheimer’s disease
5.2.3. Parkinson’s disease
5.2.4. Huntington’s disease
5.2.5. Others
CHAPTER 6. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET SIZE & FORECASTS BY TYPE 2022-2032
6.1. Segment Dashboard
6.2. Global Neurodegenerative Diseases Therapeutics Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Mammography
6.2.2. Breast ultrasound
6.2.3. Breast MRI
6.2.4. Image-guided breast biopsy
6.2.5. Other imaging techniques
CHAPTER 7. GLOBAL NEURODEGENERATIVE DISEASES THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022-2032
7.1. North America Neurodegenerative Diseases Therapeutics Market
7.1.1. U.S. Neurodegenerative Diseases Therapeutics Market
7.1.1.1. Indication breakdown size & forecasts, 2022-2032
7.1.1.2. Type breakdown size & forecasts, 2022-2032
7.1.2. Canada Neurodegenerative Diseases Therapeutics Market
7.2. Europe Neurodegenerative Diseases Therapeutics Market
7.2.1. U.K. Neurodegenerative Diseases Therapeutics Market
7.2.2. Germany Neurodegenerative Diseases Therapeutics Market
7.2.3. France Neurodegenerative Diseases Therapeutics Market
7.2.4. Spain Neurodegenerative Diseases Therapeutics Market
7.2.5. Italy Neurodegenerative Diseases Therapeutics Market
7.2.6. Rest of Europe Neurodegenerative Diseases Therapeutics Market
7.3. Asia-Pacific Neurodegenerative Diseases Therapeutics Market
7.3.1. China Neurodegenerative Diseases Therapeutics Market
7.3.2. India Neurodegenerative Diseases Therapeutics Market
7.3.3. Japan Neurodegenerative Diseases Therapeutics Market
7.3.4. Australia Neurodegenerative Diseases Therapeutics Market
7.3.5. South Korea Neurodegenerative Diseases Therapeutics Market
7.3.6. Rest of Asia Pacific Neurodegenerative Diseases Therapeutics Market
7.4. Latin America Neurodegenerative Diseases Therapeutics Market
7.4.1. Brazil Neurodegenerative Diseases Therapeutics Market
7.4.2. Mexico Neurodegenerative Diseases Therapeutics Market
7.4.3. Rest of Latin America Neurodegenerative Diseases Therapeutics Market
7.5. Middle East & Africa Neurodegenerative Diseases Therapeutics Market
7.5.1. Saudi Arabia Neurodegenerative Diseases Therapeutics Market
7.5.2. South Africa Neurodegenerative Diseases Therapeutics Market
7.5.3. Rest of Middle East & Africa Neurodegenerative Diseases Therapeutics Market
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. Company
8.1.2. Company
8.1.3. Company
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. AB Science SA
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Acadia Pharmaceuticals Inc.
8.3.3. H Lundbeck AS
8.3.4. Mitsubishi Chemical Corp.
8.3.5. Novartis AG
8.3.6. Sanofi SA
8.3.7. Teva Pharmaceutical Industries Ltd.
8.3.8. Amgen Inc.
8.3.9. AstraZeneca PLC
8.3.10. Eli Lilly and Company
8.3.11. GlaxoSmithKline plc
8.3.12. Merck & Co., Inc.
8.3.13. AbbVie Inc.
8.3.14. Biogen Inc.
8.3.15. F. Hoffmann La Roche Ltd
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Neurodegenerative Diseases Therapeutics market, report scope
TABLE 2. Global Neurodegenerative Diseases Therapeutics market estimates & forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global Neurodegenerative Diseases Therapeutics market estimates & forecasts by Indication 2022-2032 (USD Billion)
TABLE 4. Global Neurodegenerative Diseases Therapeutics market estimates & forecasts by Type 2022-2032 (USD Billion)
TABLE 5. Global Neurodegenerative Diseases Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 6. Global Neurodegenerative Diseases Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 7. Global Neurodegenerative Diseases Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 8. Global Neurodegenerative Diseases Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. Global Neurodegenerative Diseases Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. Global Neurodegenerative Diseases Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. Global Neurodegenerative Diseases Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 12. Global Neurodegenerative Diseases Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 13. Global Neurodegenerative Diseases Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 14. Global Neurodegenerative Diseases Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 15. U.S. Neurodegenerative Diseases Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 16. U.S. Neurodegenerative Diseases Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 17. U.S. Neurodegenerative Diseases Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 18. Canada Neurodegenerative Diseases Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 19. Canada Neurodegenerative Diseases Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 20. Canada Neurodegenerative Diseases Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
.....
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.
TABLE 1. Global Neurodegenerative Diseases Therapeutics market, report scope
TABLE 2. Global Neurodegenerative Diseases Therapeutics market estimates & forecasts by Region 2022-2032 (USD Billion)
TABLE 3. Global Neurodegenerative Diseases Therapeutics market estimates & forecasts by Indication 2022-2032 (USD Billion)
TABLE 4. Global Neurodegenerative Diseases Therapeutics market estimates & forecasts by Type 2022-2032 (USD Billion)
TABLE 5. Global Neurodegenerative Diseases Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 6. Global Neurodegenerative Diseases Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 7. Global Neurodegenerative Diseases Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 8. Global Neurodegenerative Diseases Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. Global Neurodegenerative Diseases Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. Global Neurodegenerative Diseases Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. Global Neurodegenerative Diseases Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 12. Global Neurodegenerative Diseases Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 13. Global Neurodegenerative Diseases Therapeutics market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 14. Global Neurodegenerative Diseases Therapeutics market by region, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 15. U.S. Neurodegenerative Diseases Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 16. U.S. Neurodegenerative Diseases Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 17. U.S. Neurodegenerative Diseases Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 18. Canada Neurodegenerative Diseases Therapeutics market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 19. Canada Neurodegenerative Diseases Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 20. Canada Neurodegenerative Diseases Therapeutics market estimates & forecasts by segment 2022-2032 (USD Billion)
.....
This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.
LIST OF FIGURES
FIG 1. Global Neurodegenerative Diseases Therapeutics market, research methodology
FIG 2. Global Neurodegenerative Diseases Therapeutics market, market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global Neurodegenerative Diseases Therapeutics market, key trends 2023
FIG 5. Global Neurodegenerative Diseases Therapeutics market, growth prospects 2022-2032
FIG 6. Global Neurodegenerative Diseases Therapeutics market, porters 5 force model
FIG 7. Global Neurodegenerative Diseases Therapeutics market, PESTEL analysis
FIG 8. Global Neurodegenerative Diseases Therapeutics market, value chain analysis
FIG 9. Global Neurodegenerative Diseases Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 10. Global Neurodegenerative Diseases Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 11. Global Neurodegenerative Diseases Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 12. Global Neurodegenerative Diseases Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 13. Global Neurodegenerative Diseases Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 14. Global Neurodegenerative Diseases Therapeutics market, regional snapshot 2022 & 2032
FIG 15. North America Neurodegenerative Diseases Therapeutics market 2022 & 2032 (USD Billion)
FIG 16. Europe Neurodegenerative Diseases Therapeutics market 2022 & 2032 (USD Billion)
FIG 17. Asia pacific Neurodegenerative Diseases Therapeutics market 2022 & 2032 (USD Billion)
FIG 18. Latin America Neurodegenerative Diseases Therapeutics market 2022 & 2032 (USD Billion)
FIG 19. Middle East & Africa Neurodegenerative Diseases Therapeutics market 2022 & 2032 (USD Billion)
FIG 20. Global Neurodegenerative Diseases Therapeutics market, company market share analysis (2023)
.....
This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.
FIG 1. Global Neurodegenerative Diseases Therapeutics market, research methodology
FIG 2. Global Neurodegenerative Diseases Therapeutics market, market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global Neurodegenerative Diseases Therapeutics market, key trends 2023
FIG 5. Global Neurodegenerative Diseases Therapeutics market, growth prospects 2022-2032
FIG 6. Global Neurodegenerative Diseases Therapeutics market, porters 5 force model
FIG 7. Global Neurodegenerative Diseases Therapeutics market, PESTEL analysis
FIG 8. Global Neurodegenerative Diseases Therapeutics market, value chain analysis
FIG 9. Global Neurodegenerative Diseases Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 10. Global Neurodegenerative Diseases Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 11. Global Neurodegenerative Diseases Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 12. Global Neurodegenerative Diseases Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 13. Global Neurodegenerative Diseases Therapeutics market by segment, 2022 & 2032 (USD Billion)
FIG 14. Global Neurodegenerative Diseases Therapeutics market, regional snapshot 2022 & 2032
FIG 15. North America Neurodegenerative Diseases Therapeutics market 2022 & 2032 (USD Billion)
FIG 16. Europe Neurodegenerative Diseases Therapeutics market 2022 & 2032 (USD Billion)
FIG 17. Asia pacific Neurodegenerative Diseases Therapeutics market 2022 & 2032 (USD Billion)
FIG 18. Latin America Neurodegenerative Diseases Therapeutics market 2022 & 2032 (USD Billion)
FIG 19. Middle East & Africa Neurodegenerative Diseases Therapeutics market 2022 & 2032 (USD Billion)
FIG 20. Global Neurodegenerative Diseases Therapeutics market, company market share analysis (2023)
.....
This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.
